Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat augmentation of clozapine in schizophrenia
NCT03263533Phase 1Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Apr 2017
- Primary completion
- Feb 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing Vorinostat Sequence with Placebo Sequence (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 10 weeks and Change in clinical cognitive symptoms at 10 weeks. Planned start Apr 2017; status: withdrawn.
02
Drugs
vorinostat
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03263533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263533.